d ribose (MedChemExpress)
Structured Review
D Ribose, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+ribose/D-Ribose/pm42849556-51-74-76
Average 93 stars, based on 8 article reviews
Images
Related Articles
CMC:Article Title: Sishen pill alleviates DSS induced colitis through AGE/RAGE/NLRP3 pathway based on transcriptomics analysis. Article Snippet: Mesalazine was from EthyPharm Pharmaceutical Co., Ltd. (Shanghai, China). .. Proteintech (Nanjing, China) provided experimental antibodies, FPS-ZM1, CMC-NA, and Enzyme-linked Immunosorbent Assay:Article Title: Sishen pill alleviates DSS induced colitis through AGE/RAGE/NLRP3 pathway based on transcriptomics analysis. Article Snippet: Mesalazine was from EthyPharm Pharmaceutical Co., Ltd. (Shanghai, China). .. Proteintech (Nanjing, China) provided experimental antibodies, FPS-ZM1, CMC-NA, and other:Article Title: Aqueous extract of Saposhnikovia divaricata root alleviates rheumatoid arthritis by acting on TNF-α and RAGE signaling pathways Article Snippet: Saffron-O and Fast Green Kit (G1371) was purchased from Beijing Solarbio Technology Co., LTD (Beijing China). Control:Article Title: Purine availability determines survival of complex I-deficient fibroblasts under OXPHOS-reliant condition. Article Snippet: Growing fibroblasts in medium containing galactose instead of glucose makes cells more dependent on oxidative phosphorylation (OXPHOS) rather than glycolysis.. Recently, it has been shown that treatment with nicotinamide adenine dinucleotide (NAD) improves cell viability of human OXPHOS Complex I-deficient skin fibroblasts in this OXPHOS-reliant condition.. To study the effects of NAD precursors in this model, we supplemented the cells with trigonelline (TG), nicotinamide (NAM), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and found no improvement in cell viability, while supplementation with niacin (NA) did partially. In Vitro:Article Title: Tumor-derived HMGB1 induces CD62L dim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer Article Snippet: .. The following reagents/additives were used for in vitro neutrophils intervention. (1) concentrated tissue and cell culture supernatant obtained by ultrafiltration tube centrifugation at 3000 × g for 15 min in Fig. (Millipore, #UFC900396) (2) TLR agonist including Pam3CSK4 (10 ng/mL, TLR2/TLR1 agonist, InvivoGen, #tlrl-pms), FSL-1(10 ng/mL, TLR2/6 agonist, InvivoGen, #tlrl-fsl), Poly(I:C) (LMW) (100 ng/ml, TLR3 agonist, InvivoGen, #tlrl-picw), MPLA-SM (1 μg/mL, TLR4 agonist, InvivoGen, #tlrl-mpla), FLA-ST (1 μg/mL, TLR5 agonist, InvivoGen, #tlrl-stfla), R848 (1 μg/mL, TLR7/8 agonist, InvivoGen, #tlrl-r848), TLR9 Agonist Kit containing ODN 1585, ODN 1826, ODN 2395 (1 μg/mL, TLR9 agonist, InvivoGen, #tlrl-kit9m) in Fig. ; (3) Cell Culture:Article Title: Tumor-derived HMGB1 induces CD62L dim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer Article Snippet: .. The following reagents/additives were used for in vitro neutrophils intervention. (1) concentrated tissue and cell culture supernatant obtained by ultrafiltration tube centrifugation at 3000 × g for 15 min in Fig. (Millipore, #UFC900396) (2) TLR agonist including Pam3CSK4 (10 ng/mL, TLR2/TLR1 agonist, InvivoGen, #tlrl-pms), FSL-1(10 ng/mL, TLR2/6 agonist, InvivoGen, #tlrl-fsl), Poly(I:C) (LMW) (100 ng/ml, TLR3 agonist, InvivoGen, #tlrl-picw), MPLA-SM (1 μg/mL, TLR4 agonist, InvivoGen, #tlrl-mpla), FLA-ST (1 μg/mL, TLR5 agonist, InvivoGen, #tlrl-stfla), R848 (1 μg/mL, TLR7/8 agonist, InvivoGen, #tlrl-r848), TLR9 Agonist Kit containing ODN 1585, ODN 1826, ODN 2395 (1 μg/mL, TLR9 agonist, InvivoGen, #tlrl-kit9m) in Fig. ; (3) Centrifugation:Article Title: Tumor-derived HMGB1 induces CD62L dim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer Article Snippet: .. The following reagents/additives were used for in vitro neutrophils intervention. (1) concentrated tissue and cell culture supernatant obtained by ultrafiltration tube centrifugation at 3000 × g for 15 min in Fig. (Millipore, #UFC900396) (2) TLR agonist including Pam3CSK4 (10 ng/mL, TLR2/TLR1 agonist, InvivoGen, #tlrl-pms), FSL-1(10 ng/mL, TLR2/6 agonist, InvivoGen, #tlrl-fsl), Poly(I:C) (LMW) (100 ng/ml, TLR3 agonist, InvivoGen, #tlrl-picw), MPLA-SM (1 μg/mL, TLR4 agonist, InvivoGen, #tlrl-mpla), FLA-ST (1 μg/mL, TLR5 agonist, InvivoGen, #tlrl-stfla), R848 (1 μg/mL, TLR7/8 agonist, InvivoGen, #tlrl-r848), TLR9 Agonist Kit containing ODN 1585, ODN 1826, ODN 2395 (1 μg/mL, TLR9 agonist, InvivoGen, #tlrl-kit9m) in Fig. ; (3) Recombinant:Article Title: Tumor-derived HMGB1 induces CD62L dim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer Article Snippet: .. The following reagents/additives were used for in vitro neutrophils intervention. (1) concentrated tissue and cell culture supernatant obtained by ultrafiltration tube centrifugation at 3000 × g for 15 min in Fig. (Millipore, #UFC900396) (2) TLR agonist including Pam3CSK4 (10 ng/mL, TLR2/TLR1 agonist, InvivoGen, #tlrl-pms), FSL-1(10 ng/mL, TLR2/6 agonist, InvivoGen, #tlrl-fsl), Poly(I:C) (LMW) (100 ng/ml, TLR3 agonist, InvivoGen, #tlrl-picw), MPLA-SM (1 μg/mL, TLR4 agonist, InvivoGen, #tlrl-mpla), FLA-ST (1 μg/mL, TLR5 agonist, InvivoGen, #tlrl-stfla), R848 (1 μg/mL, TLR7/8 agonist, InvivoGen, #tlrl-r848), TLR9 Agonist Kit containing ODN 1585, ODN 1826, ODN 2395 (1 μg/mL, TLR9 agonist, InvivoGen, #tlrl-kit9m) in Fig. ; (3) Flow Cytometry:Article Title: Tumor-derived HMGB1 induces CD62L dim neutrophil polarization and promotes lung metastasis in triple-negative breast cancer Article Snippet: .. The following reagents/additives were used for in vitro neutrophils intervention. (1) concentrated tissue and cell culture supernatant obtained by ultrafiltration tube centrifugation at 3000 × g for 15 min in Fig. (Millipore, #UFC900396) (2) TLR agonist including Pam3CSK4 (10 ng/mL, TLR2/TLR1 agonist, InvivoGen, #tlrl-pms), FSL-1(10 ng/mL, TLR2/6 agonist, InvivoGen, #tlrl-fsl), Poly(I:C) (LMW) (100 ng/ml, TLR3 agonist, InvivoGen, #tlrl-picw), MPLA-SM (1 μg/mL, TLR4 agonist, InvivoGen, #tlrl-mpla), FLA-ST (1 μg/mL, TLR5 agonist, InvivoGen, #tlrl-stfla), R848 (1 μg/mL, TLR7/8 agonist, InvivoGen, #tlrl-r848), TLR9 Agonist Kit containing ODN 1585, ODN 1826, ODN 2395 (1 μg/mL, TLR9 agonist, InvivoGen, #tlrl-kit9m) in Fig. ; (3) |
